Updated Jul 16, 2026
BIENAIME JEAN JACQUES has filed 11 SEC Form 4 filings across 4 companies in the last 90 days — active on both sides. Lifetime open-market purchases: $660K. Lifetime open-market sales: $204K. Historical track record: 3/5 stars across 4 tracked purchases.
InsiderAlpha computes a forward-return-based score for every insider with enough Form 4 purchase history. The metrics below reflect realised performance after each tracked open-market purchase.
| InsiderAlpha rating | ★★★☆☆ (3/5) |
|---|---|
| Total purchases tracked | 4 |
| Purchases with forward-return data | 4 |
| 30-day win rate | 7500% |
| 90-day win rate | 2500% |
| Avg 5-day return | -360.83% |
| Avg 30-day return | +251.09% |
| Avg 90-day return | -1015.28% |
| Best 30-day return | +1057.27% |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-17 | KROS | Keros Therapeutics, Inc. | P — Open-market purchase | 1.0K | $10.19 | $10K |
| 2026-06-10 | INCY | INCYTE CORP | A — Grant or award | 1.6K | $0.00 | |
| 2026-06-09 | IMNM | Immunome Inc. | P — Open-market purchase | 1.0K | $19.27 | $19K |
| 2026-06-09 | IMNM | Immunome Inc. | P — Open-market purchase | 3.5K | $19.46 | $68K |
| 2026-06-09 | IMNM | Immunome Inc. | P — Open-market purchase | 6.0K | $19.48 | $117K |
| 2026-06-09 | IMNM | Immunome Inc. | S — Open-market sale | 10.0K | $19.41 | $194K |
| 2026-06-09 | IMNM | Immunome Inc. | S — Open-market sale | 500 | $19.44 | $10K |
| 2026-06-05 | KROS | Keros Therapeutics, Inc. | A — Grant or award | 7.1K | $0.00 | |
| 2026-06-01 | ASND | Ascendis Pharma A/S | P — Open-market purchase | 100 | $223.50 | $22K |
| 2026-06-01 | ASND | Ascendis Pharma A/S | P — Open-market purchase | 200 | $222.30 | $44K |
| 2026-06-01 | ASND | Ascendis Pharma A/S | P — Open-market purchase | 200 | $223.76 | $45K |
| 2026-05-28 | INCY | INCYTE CORP | F — Tax withholding / forfeiture | 13.1K | $97.10 | $1.27M |
| 2026-05-28 | INCY | INCYTE CORP | M — Option exercise | 15.0K | $84.53 | $1.27M |
| 2026-05-27 | ASND | Ascendis Pharma A/S | P — Open-market purchase | 200 | $239.37 | $48K |
| 2026-05-27 | ASND | Ascendis Pharma A/S | P — Open-market purchase | 200 | $236.24 | $47K |
| 2026-05-19 | KROS | Keros Therapeutics, Inc. | P — Open-market purchase | 1.0K | $10.58 | $11K |
| 2026-05-19 | IMNM | Immunome Inc. | P — Open-market purchase | 5.0K | $20.70 | $104K |
| 2026-04-17 | KROS | Keros Therapeutics, Inc. | P — Open-market purchase | 1.0K | $11.70 | $12K |
| 2026-03-12 | IMNM | Immunome Inc. | P — Open-market purchase | 1.0K | $21.55 | $22K |
| 2026-03-12 | IMNM | Immunome Inc. | P — Open-market purchase | 1.0K | $22.12 | $22K |
BIENAIME JEAN JACQUES is a corporate insider — currently tracked as Insider of Keros Therapeutics, Inc. (KROS). InsiderAlpha tracks every SEC Form 4 filing in real time.
11 primary Form 4 filings in the last 90 days, covering 4 companies.
Recorded transactions: 16 open-market purchases ($660K) and 2 open-market sales ($204K) across all tracked filings.
Across 4 tracked purchases, BIENAIME JEAN JACQUES averaged +251.1% avg 30-day return with a 7500% 30-day win rate. InsiderAlpha rates the track record at 3/5 stars.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live BIENAIME JEAN JACQUES profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.